Brief: Ondine Biomedical Says LANTERN Phase 3 Study To Report Top-Line Results In Spring 2026
10/03/2026 07:50
March 10 (Reuters) - Ondine Biomedical Inc OBI.L: ONDINE BIOMEDICAL - ONDINE PROVIDES UPDATE ON US PHASE 3 PIVOTAL STUDY ONDINE BIOMEDICAL INC - LANTERN PHASE 3 STUDY TO REPORT TOP-LINE RESULTS IN SPRING 2026 Source text: ID:nRSJ0241Wa Further company coverage: OBI.L ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ondine Biomedical
See all newsBrief: Ondine Lantern Phase 3 Database Lock Expected Within A Week; Top-Line Results In 1-2 Weeks
Ondine Biomedical - Leeds Drops SSIs by 78.5% in Complex Brain Surgery
Brief: Ondine Biomedical Expects 2026 To Be A Defining Year For Company
Ondine Biomedical - Notice of AGM
Ondine Biomedical - 2025 Full Year Results and Annual Report